The CDC now recommends 11 vaccines for routine administration in childhood, which it says better allows for “flexibility and ...

Takeda and Protagonist Therapeutics have jointly submitted a NDA seeking approval from the US FDA for rusfertide to treat ...

Reporter Ross Law and editors Abigail Beaney and Robert Barrie reflect on a busy 2025, along with discusing forecasts for ...

According to the registration form, Aktis intends to use a large portion of the IPO proceeds on the two programmes. Around ...

Arrowhead Pharmaceuticals has received authorisation from Health Canada for its siRNA medicine, Redemplo, for adults with FCS ...

Sanofi's $2.56bn bispecific autoimmune deal with Earendil Labs is the second in recent history, and will bolster the French ...

Insilico Medicine has entered a multi-year R&D collaboration with Servier, worth up to $888m, to develop and discover new ...

NICE has recommended Tysabri and biosimilar Tyruko as an option for patients with highly active relapsing-remitting multiple ...

Samsung Bioepis has started direct commercialisation of Byooviz, a biosimilar to Genentech’s Lucentis (ranibizumab), in ...

In early December, the 2025 updates of China’s NRDL were finalised with a total of 114 drugs, including Western drugs and ...

The AMD market is expected to grow at a CAGR of 10.2% over the course of the forecast period (2024–34), reaching $20.5bn ...

Outlook Therapeutics has received the US FDA's CRL regarding the BLA resubmission for ONS-5010/LYTENAVA to treat wet AMD.